Ghrelin is a 28-amino acid peptide hormone primarily produced in the stomach and hypothalamus. It serves as the endogenous ligand for the growth hormone secretagogue receptor (GHSR1a) and plays crucial roles in growth hormone secretion, appetite regulation, energy homeostasis, and neuroprotection. Ghrelin signaling has emerged as a potential therapeutic target for neurodegenerative diseases due to its effects on mitochondrial function, neuroinflammation, and synaptic plasticity .
First discovered in 1999 and formally identified as the natural ligand for GHSR1a in 2004 , ghrelin represents a unique hormonal system that bridges metabolic and neural function. Unlike most peptide hormones, ghrelin requires a unique post-translational modification—O-octanoylation at serine-3—for biological activity. This modification, catalyzed by ghrelin O-acyltransferase (GOAT), is essential for binding to GHSR1a and subsequent signaling cascades.
The ghrelin system has garnered significant attention in neurodegeneration research due to its pleiotropic effects on brain function. Beyond its well-established role in energy homeostasis, ghrelin exerts direct neuroprotective effects through multiple mechanisms including anti-apoptotic signaling, antioxidant defense, anti-inflammatory modulation, and enhancement of synaptic plasticity . These effects position ghrelin as a promising therapeutic target for conditions like Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
¶ Structure and Synthesis
Ghrelin is encoded by the GHRL gene located on chromosome 3 (3p25-26) and undergoes unique post-translational modification:
Gene Structure
- Single exon gene encoding prepro-ghrelin (117 amino acids)
- Alternative splicing produces multiple isoforms
- GOAT (MBOAT4) encoded by the MBOAT4 gene
Post-Translational Processing
- Acylation: Ghrelin is uniquely O-octanoylated at serine-3 by ghrelin O-acyltransferase (GOAT)
- This modification is essential for binding to GHSR1a
- Both acylated (active) and non-acylated (inactive) forms exist in circulation
- The acylated form constitutes only 5-10% of total circulating ghrelin
Isoforms
- Des-acyl ghrelin: Non-octanoylated form, biologically inactive at GHSR1a
- Obestatin: Alternative splice product with distinct biological activities
- AGRP-derived peptides: Processed from prepro-ghrelin gene products
Ghrelin signals through two main receptors :
GHSR1a (Growth Hormone Secretagogue Receptor 1a)
- High-affinity receptor for acylated ghrelin
- Gαq/11-coupled GPCR expressed throughout the brain
- Expressed in hypothalamus, hippocampus, cortex, substantia nigra, and striatum
- Responsible for most central nervous system effects
GHSR1b
- Truncated splice variant with 7 transmembrane domains
- Lower affinity for ghrelin
- Functions may include receptor dimerization and regulation
- Less understood biological roles
flowchart TD
A["Ghrelin"] --> B["GHSR1a"]
A --> C["GHSR1b"]
B --> D["Gαq/11"]
D --> E["PLC"]
E --> F["IP3/DAG"]
F --> G["Ca²⁺ Release"]
F --> H["PKC"]
B --> I["Gαs"]
I --> J["Adenylyl Cyclase"]
J --> K["↑cAMP"]
K --> L["PKA"]
L --> M["CREB"]
M --> N["Gene Transcription"]
H --> O["ERK1/2"]
O --> P["Cell Proliferation"]
G --> Q["Neurotransmitter Release"]
Q --> R["Neuroprotection"]
N --> R
P --> S["GH Release"]
B --> T["β-arrestin"]
T --> U["β-catenin"]
U --> V["Cell Survival"]
style A fill:#e1f5fe,stroke:#333
style R fill:#c8e6c9,stroke:#333
style V fill:#c8e6c9,stroke:#333
Key signaling pathways:
Downstream Signaling Cascades
- PLC/IP3/Ca²⁺: Calcium signaling and neurotransmitter release
- cAMP/PKA: Growth hormone secretion and gene transcription via CREB
- ERK1/2: Cell proliferation and neuroplasticity
- PI3K/Akt: Cell survival and anti-apoptotic signaling
- JAK/STAT: Cytokine signaling modulation
- β-catenin: Cell survival through β-arrestin recruitment
Ghrelin can cross the blood-brain barrier through multiple mechanisms:
- Saturable transport: Active transport system with finite capacity
- Circumventricular organs: Areas lacking BBB allow direct access
- Receptor-mediated transcytosis: GHSR1a-mediated uptake
- The blood-brain barrier transport is direction-dependent and can be modulated by metabolic state
The hypothalamus contains the highest density of ghrelin-responsive neurons:
Arcuate Nucleus (ARC)
- Primary site of ghrelin action in the brain
- Co-localization with NPY/AgRP and POMC neurons
- Integration of metabolic signals with neuroendocrine control
Paraventricular Nucleus (PVN)
- Autonomic and neuroendocrine regulation
- Stress response modulation
Dorsomedial Hypothalamus (DMH)
- Energy expenditure control
- Thermogenesis regulation
Hippocampus
- CA1, CA3, and dentate gyrus expression
- Critical for memory consolidation and spatial navigation
- Synaptic plasticity modulation
Cortex
- Prefrontal cortex: executive function
- Entorhinal cortex: early AD pathology site
Substantia Nigra
Striatum
- Motor control and habit formation
- Integration with dopaminergic signaling
Ghrelin affects amyloid-beta (Aβ) metabolism through multiple mechanisms :
Aβ Production and Processing
- Modulation of amyloid precursor protein (APP) processing
- Reduced β-secretase (BACE1) activity
- Enhanced α-secretase (ADAM10) activity
- Shift toward non-amyloidogenic processing
Aβ-Induced Neurotoxicity Protection
- Reduced Aβ-induced cell death in neuronal cultures
- Attenuation of Aβ-induced oxidative stress
- Protection against Aβ-induced synaptic dysfunction
- Preservation of mitochondrial integrity
Aβ Clearance Enhancement
- Enhanced autophagy-mediated clearance
- Improved proteasomal degradation
- Modulation of the glymphatic system
Ghrelin enhances synaptic function through multiple pathways :
Long-Term Potentiation (LTP)
- Enhanced hippocampal LTP induction and maintenance
- NMDA receptor modulation
- AMPA receptor trafficking improvements
- Postsynaptic density protein (PSD95) upregulation
Dendritic Morphology
- Increased dendritic spine density
- Enhanced mushroom spine formation
- Improved dendritic complexity
Memory Performance
- Better spatial memory in AD models
- Improved object recognition
- Enhanced contextual fear conditioning
- Reversal of memory deficits in aged animals
Ghrelin exerts potent anti-inflammatory effects :
Microglial Modulation
- Reduced microglial activation
- Shift toward anti-inflammatory (M2) phenotype
- Decreased phagocytic activity (potentially beneficial in early AD)
Cytokine Regulation
- Reduced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
- Increased anti-inflammatory cytokines (IL-10, TGF-β)
- NF-κB pathway inhibition
- NLRP3 inflammasome suppression
Neuroimmune Interface
- Modulation of peripheral immune-brain communication
- Reduced blood-brain barrier permeability
- T cell brain infiltration reduction
Ghrelin improves brain energy metabolism [@ghrelin2021b]:
Glucose Metabolism
- Enhanced glucose uptake via GLUT1 and GLUT3
- Improved cerebral glucose utilization
- Reduced cerebral hypometabolism
Mitochondrial Function
- Enhanced mitochondrial biogenesis via PGC-1α
- Improved electron transport chain efficiency
- Reduced mitochondrial dysfunction
Metabolic Stress
- Reduced ER stress
- Improved energy sensing via AMPK
- Protection against metabolic insults
Ghrelin provides robust protection to dopaminergic neurons :
Toxin Protection
- Reduced 6-OHDA-induced dopaminergic neuron death
- Attenuated MPTP-induced parkinsonism
- Protection against rotenone toxicity
Tyrosine Hydroxylase Preservation
- Preservation of TH-positive neuron number
- Maintained TH expression levels
- Protected dopamine synthesis capacity
Motor Function Improvement
- Improved rota-rod performance
- Enhanced forelimb use
- Reduced akinesia
- Better gait parameters
Ghrelin improves mitochondrial health through multiple mechanisms :
Mitochondrial Biogenesis
- PGC-1α activation
- TFAM upregulation
- Enhanced mtDNA replication
Complex Activity
- Improved Complex I activity (particularly vulnerable in PD)
- Enhanced Complex IV function
- Better ATP production efficiency
Antioxidant Defense
- Upregulation of SOD, catalase, glutathione peroxidase
- Reduced lipid peroxidation
- Protected mitochondrial DNA from oxidative damage
Dynamics
- Improved fission/fusion balance
- Enhanced mitophagy
- Better mitochondrial trafficking
Ghrelin modulates autophagy pathways :
Alpha-Synuclein Clearance
- Enhanced clearance of alpha-synuclein aggregates
- Reduced intracellular accumulation
- Improved proteostasis
Lysosomal Function
- Enhanced lysosomal activity
- Improved cathepsin activity
- Better autophagosome-lysosome fusion
Selective Autophagy
- Specific enhancement of mitophagy
- Selective removal of damaged mitochondria
- Regulation of aggrephagy
- Motor neuron protection via anti-apoptotic mechanisms
- Improved survival in SOD1 transgenic models
- Reduced glutamate excitotoxicity
- Attenuated neuroinflammation
- Neuroprotective effects in striatal neurons
- Improved motor function
- Enhanced mitochondrial function
- Reduced mutant huntingtin aggregation
- Myelin protection
- Reduced inflammatory demyelination
- Neurotrophic support
- Synaptic protection
- Reduced tau pathology
- Behavioral symptom modulation
- CSF ghrelin as potential AD biomarker
- Serum ghrelin as PD progression marker
- GHSR1a expression as therapeutic target indicator
- Ghrelin and GHSR1a agonists in Phase 1/2 trials for AD and PD
- GH Secretagogues in cognitive impairment
- GOAT inhibitors being explored for metabolic disorders
- Novel ghrelin analogs with improved blood-brain barrier penetration in development
In development:
- Tabimorelin: Synthetic GHSR1a agonist, cognitive effects in Phase I
- Relamorelin: Ghrelin analog with improved stability, diabetes studies
- HM01: GHSR1a biased agonist, neuroprotection in preclinical models
- Anamorelin: Appetite enhancement, oncology applications
- Macimorelin: Diagnostic agent for GH deficiency
Challenges:
- Blood-brain barrier penetration
- Optimal dosing regimens
- Long-term safety profile
- Ghrelin gene therapy
- GOAT inhibitors for metabolic modulation
- Small molecule GHSR1a modulators
- Peptide-based GHSR1a agonists with enhanced stability
- β-arrestin biased agonists for improved safety
- Intranasal delivery for direct brain targeting
- Subcutaneous administration for systemic delivery
- Exosome-based delivery systems
- Focused ultrasound-enhanced delivery
| Mechanism |
AD |
PD |
ALS |
HD |
| Anti-apoptotic |
✓ |
✓ |
✓ |
✓ |
| Anti-inflammatory |
✓ |
✓ |
✓ |
✓ |
| Mitochondrial support |
✓ |
✓ |
✓ |
✓ |
| Synaptic plasticity |
✓ |
✓ |
— |
✓ |
| Autophagy enhancement |
— |
✓ |
✓ |
✓ |
| Neurogenesis |
✓ |
✓ |
✓ |
✓ |
| Memory enhancement |
✓ |
— |
— |
✓ |
- Optimal delivery methods for CNS targeting
- Long-term safety of GHSR1a activation
- Role of GOAT in neurodegeneration
- Biomarkers for treatment response
- Optimal GHSR1a vs. GHSR1b selectivity
- β-arrestin pathway contributions